Profile data is unavailable for this security.
About the company
Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on developing and commercializing differentiated products in ophthalmology. The Company is focused on building its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on specialized therapeutic areas. Its products include ZIMED PF and PAUL GLAUCOMA IMPLANT. PAUL is a glaucoma drainage device designed to regulate intraocular pressure in the patient’s eyes and prevent further progression of the disease and is already available in over 40 countries around the world. ZIMED PF is the first available multi-dose, preservative free, bimatoprost containing product in Canada. The Company is also developing REV-0100, which is in preclinical development as a treatment for Stargardt disease.
- Revenue in CAD (TTM)918.47k
- Net income in CAD-656.34k
- Incorporated2013
- Employees12.00
- LocationAequus Pharmaceuticals IncSuite 2820, 200 Granville StreetVANCOUVER V6C 1S4CanadaCAN
- Phone+1 (604) 336-7906
- Fax+1 (604) 336-7906
- Websitehttps://www.aequuspharma.ca/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aequus Pharmaceuticals Inc | 918.47k | -656.34k | 663.17k | 12.00 | -- | -- | -- | 0.722 | -0.005 | -0.005 | 0.0069 | -0.052 | 1.74 | 7.59 | 7.95 | -- | -124.52 | -97.48 | -- | -- | 56.95 | -- | -71.46 | -148.91 | 0.027 | -2.08 | -- | -- | 129.20 | -18.58 | 26.55 | -- | -- | -- |
| Lumiera Health Inc | 594.05k | -2.37m | 847.17k | -- | -- | -- | -- | 1.43 | -0.0139 | -0.0139 | 0.0035 | -0.0137 | 0.5096 | 2.13 | 11.78 | -- | -202.92 | -- | -- | -- | 13.17 | -- | -398.18 | -- | 0.0395 | -2.10 | -- | -- | 46.91 | -- | -188.58 | -- | -- | -- |
| Vitality Products Inc | 870.37k | -48.94k | 1.24m | -- | -- | -- | -- | 1.43 | -0.0012 | -0.0012 | 0.021 | -0.0364 | 1.29 | 2.40 | 7.61 | -- | -7.23 | -30.11 | -- | -- | 72.08 | 73.52 | -5.62 | -42.71 | 0.1486 | -- | -- | -- | 0.705 | 5.10 | 45.71 | -- | -- | -- |
| Genix Pharmaceuticals Corp | 70.00 | -88.75k | 1.53m | -- | -- | -- | -- | 21,865.76 | -0.0015 | -0.0015 | 0.00 | -0.0241 | 0.0005 | -- | 0.0239 | -- | -68.30 | -54.07 | -- | -75.58 | -1,428.57 | -- | -126,785.70 | -48,255.79 | -- | -1.37 | -- | -- | -67.21 | -50.58 | 98.33 | -- | -- | -- |
